Skip to main content
. 2019 Jun 3;4:25. doi: 10.1038/s41541-019-0117-5

Table 1.

Baseline characteristics

Vaccine groups Placebo group All
16 µg (n = 24) 32 µg (n = 25) 64 µg (n = 23) Placebo (n = 14)
CD4 < 350 CD4 ≥ 350 CD4 < 350 CD4 ≥ 350 CD4 < 350 CD4 ≥ 350 CD4 < 350 CD4 ≥ 350
N 14 10 9 16 8 15 6 8 86
% Men 10 (71.4) 9 (90.0) 7 (77.8) 12 (75.3) 7 (87.5) 14 (93.3) 4 (66.7) 5 (62.5) 68 (79.1)
White race, % 7 (50.0) 7 (70.0) 5 (55.6) 8 (50.0) 6 (75.0) 11 (73.3) 4 (66.7) 4 (50.0) 52 (60.5)
Age (years) 44 (39–50) 48 (43–51) 48 (42–51) 48 (42–51) 54 (42–55) 47 (43–54) 55 (46–56) 50 (43–53) 48 (42–54)
HIV duration (years) 7.5 (5.0–13.1) 16.6 (6.4–24.6) 10.1 (5.5–15.9) 10.6 (7.9–23.3) 7.1 (3.7–19.4) 15.3 (10.9–20.6) 25.7 (5.7–27.7) 12.4 (5.1–20.6) 11.9 (5.5–22.1)
cART duration (years) 7.4 (4.4–26.1) 13.4 (2.3–18.5) 8.2 (4.1–21.7) 9.3 (6.9–16.1) 6.3 (3.2–13.3) 12.7 (7.4–19.6) 8.6 (3.2–23.1) 10.2 (4.9–24.9) 9.3 (5.1–17.8)
Nadir CD4 count (c/mm3) 133 (75–170) 170 (88–232) 160 (140–171) 168 (81–238) 124 (86–172) 199 (106–246) 85 (64–122) 244 (166–305) 159 (90–213)
CD4 count (c/mm3) 269 (249–301) 444 (412–481) 280 (267–307) 415 (396–435) 306 (286–327) 410 (364–464) 289 (257–33) 415 (369–434) 364 (300–426)
% CD4 22.9 (17.0–28.5) 29.8 (27.5–37.2) 24.2 (22.5–28.5) 27.0 (22.9–33.0) 26.2 (18.0–36.6) 25.5 (21.5–32.0) 22.5 (21.5–31.0) 30.8 (27.8–35.0) 27.1 (19.8–32.2)
CD4/CD8 ratio 0.50 (035–0.77) 0.85 (0.58–1.07) 0.58 (0.47–0.90) 0.65 (0.54–1.04) 0.47 (0.40–0.91) 0.59 (0.36–0.83) 0.46 (0.37–0.65) 0.78 (0.66–0.93) 0.62 (0.40–0.91)
HIV DNA (copies/106 PBMC) 841 (603–1122) 602 (398–872) 649 (306–1004) 739 (422–929) 786 (384–1113) 691 (259–1463) 1403 (426–2369) 347 (191–985) 738 (384–1088)

No statistically significant difference has been observed across study arms for any parameter. Data are in (%) or median (IQR)